TRANSTHERA-B (02617): Jieentai has issued its first clinical prescriptions in multiple provinces, with simultaneous stocking completed at DTP pharmacies in multiple locations nationwide.

TRANSTHERA-B (02617) announced that the company's independently developed Class 1 new drug Jieentai (Tengotinib Tablets) has received conditional marketing approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable cholangiocarcinoma who have previously received systemic therapy and FGFR inhibitor therapy and who have fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement. In September 2026, the "Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Biliary Tract Malignancies" was officially released, and Jieentai was included in the guidelines as a Class II recommendation, Category 2A, for the treatment of advanced biliary tract malignancies. Jieentai is the first treatment drug approved for marketing in China for this indication, and is expected to benefit patients with FGFR-mutant cholangiocarcinoma after resistance, filling the guideline gap in the treatment of advanced biliary tract malignancies. On September 9, 2026, the first batch of Jieentai products completed production and successfully left the factory. On September 17, 2026, the first batch of Jieentai products was officially shipped from commercial channels to pharmacies across the country, officially launching nationwide commercial supply; on the same day, Jieentai issued the country's first prescription at Peking University Cancer Hospital, marking the official entry of Jieentai into the commercial sales stage in China. Recently, Jieentai has issued its first clinical prescriptions in Beijing, Shanghai, Guangdong, Jiangsu and other provinces, with simultaneous stocking completed at DTP pharmacies in multiple locations nationwide. In the future, Jieentai will rely on the strong terminal distribution capabilities and mature warehousing and logistics network of SINOPHARM Jiangsu Co., Ltd. (Sinopharm Jiangsu) to further expand sales in multiple retail pharmacies across 21 provinces, municipalities and autonomous regions nationwide, fully establishing the nationwide commercial supply system.